Bausch Health Cos (BHC) to Release Earnings on Wednesday

Bausch Health Cos (NYSE:BHC) is anticipated to post its Q2 2025 quarterly earnings results after the market closes on Wednesday, July 30th. Analysts expect Bausch Health Cos to post earnings of $0.93 per share and revenue of $2.47 billion for the quarter.

Bausch Health Cos Price Performance

Shares of NYSE BHC opened at $6.88 on Tuesday. The stock has a market capitalization of $2.55 billion, a P/E ratio of -62.55 and a beta of 0.41. Bausch Health Cos has a 1-year low of $4.25 and a 1-year high of $9.85. The business has a fifty day moving average price of $5.84 and a 200 day moving average price of $6.12.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on BHC. Royal Bank Of Canada upped their target price on Bausch Health Cos from $8.50 to $10.00 and gave the company a “sector perform” rating in a research report on Friday, May 2nd. Wall Street Zen lowered Bausch Health Cos from a “buy” rating to a “hold” rating in a research report on Saturday, May 10th. One equities research analyst has rated the stock with a sell rating and five have given a hold rating to the company. According to data from MarketBeat, Bausch Health Cos presently has an average rating of “Hold” and a consensus target price of $7.38.

Insider Transactions at Bausch Health Cos

In other Bausch Health Cos news, Director John Paulson bought 3,564,059 shares of Bausch Health Cos stock in a transaction that occurred on Friday, June 13th. The shares were bought at an average cost of $5.94 per share, with a total value of $21,170,510.46. Following the transaction, the director directly owned 32,791,702 shares of the company’s stock, valued at approximately $194,782,709.88. This represents a 12.19% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Over the last quarter, insiders bought 6,352,667 shares of company stock worth $35,870,767. Corporate insiders own 8.12% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of BHC. Dynamic Technology Lab Private Ltd acquired a new position in shares of Bausch Health Cos in the first quarter valued at about $68,000. Jones Financial Companies Lllp increased its holdings in shares of Bausch Health Cos by 1,548.9% in the first quarter. Jones Financial Companies Lllp now owns 24,965 shares of the company’s stock valued at $162,000 after purchasing an additional 23,451 shares during the period. Goldman Sachs Group Inc. increased its holdings in shares of Bausch Health Cos by 97.1% in the first quarter. Goldman Sachs Group Inc. now owns 948,322 shares of the company’s stock valued at $6,136,000 after purchasing an additional 467,270 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Bausch Health Cos by 3.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 324,847 shares of the company’s stock valued at $2,102,000 after purchasing an additional 9,834 shares during the period. 78.65% of the stock is owned by institutional investors and hedge funds.

About Bausch Health Cos

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.